Гистиоцитарные заболевания у собак и кошек
Онкология

Гистиоцитарные заболевания у собак и кошек

Авторы: Игнатенко Н., к.в.н., резидент отделения онкологии клиники для мелких животных Мюнхенского университета имени Людвига и Максимилиана, Германия, консультант клиники «Зооветсервис», Киев, Украина.
Абраменко И. В., д.м.н., профессор, главный научный сотрудник лаборатории молекулярной биологии отдела клинической иммунологии, Национальный научный центр радиационной медицины, Киев, Украина.

Резюме. Обзор посвящен характеристике заболеваний гистиоцитарного происхождения у мелких домашних животных (собак и котов). Представлены основные сведения о происхождении клеток гистиоцитарной линии гемопоэза, классификация заболеваний гистиоцитарной природы, охарактеризованы основные нозологические формы заболеваний, клиническая картина, морфологическая характеристика клеток в аспекте дифференциальной диагностики, ключевые подходы к терапии.

Summary. The review is devoted to the characterization of histiocytic diseases in small domestic animals (dogs and cats). The information concerning the origin of histiocytic cells, the classification of histiocytic diseases, their main nosological forms, the clinical characteristics, the morphological peculiarities of the tumor cells in the aspect of differential diagnosis, and the main approaches to therapy are presented.

Литература:
  1. Collin M., Milne P. Langerhans cell origin and regulation Curr Opin Hematol. 2016; 23(1): 28–35. 
  2. Shortman K., Naik S.H. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol. 2007; 7(1):19–30.
  3. Moore P.F., Schrenzel M.D., Affolter V.K., Olivry T., Naydan D. Canine cutaneous histiocytoma is an epidermotropic Langerhans cell histiocytosis that expresses CD1 and specific beta 2-integrin molecules. Am J Pathol. 1996; 148(5):1699–1708.
  4. Moore P.F. A review of histiocytic diseases of dogs and cats. Vet Pathol. 2014; 51(1):167–184. doi: 10.1177/0300985813510413.
  5. Schjaerff M., Keller S.M., Fass J., Froenicke L., Grahn R.A., Lyons L., Affolter V.K., Kristensen A.T., Moore P.F. Refinement of the canine CD1 locus topology and investigation of antibody binding to recombinant canine CD1 isoforms. Immunogenetics. 2016; 68(3):191–204. doi: 10.1007/s00251-015-0889-3.  
  6. Mizumoto N.,  Takashima А.  CD1a and langerin: acting as more than Langerhans cell markers. J Clin Invest. 2004; 113(5): 658–660. doi:  [10.1172/JCI200421140]. 
  7. Figdor C.G., van Kooyk Y., Adema G.J. C-type lectin receptors on dendritic cells and Langerhans cells. Nat Rev Immunol. 2002; 2: 77–84.
  8. Mulligan R.M. Neoplastic diseases of dogs; mast cell sarcoma, lymphosarcoma, histiocytoma. Arch Pathol (Chic). 1948; 46(5): 477–492. 
  9. Schmidt J.M., North S.M., Freeman K.P., Ramiro-Ibañez F. Canine paediatric oncology: retrospective assessment of 9522 tumours in dogs up to 12 months (1993-2008). Vet Comp Oncol. 2010; 8(4): 283–292. doi: 10.1111/j.1476-5829.2010.00226.x.
  10. Taylor D.O., Dorn C.R., Luis O.H. Morphologic and biologic characteristics of the canine cutaneous histiocytoma. Cancer Res. 1969; 29(1): 83–92.
  11. Paździor-Czapula K., Rotkiewicz T., Otrocka-Domagała I., Gesek M., Śmiech A. Morphology and immunophenotype of canine cutaneous histiocytic tumours with particular emphasis on diagnostic application. Vet Res Commun. 2015; 39(1):7–17. doi: 10.1007/s11259-014-9622-1. 
  12. Fernandez N.J., West K.H., Jackson M.L., Kidney B.A. Immunohistochemical and histochemical stains for differentiating canine cutaneous round cell tumors. Vet Pathol. 2005; 42(4): 437–445.
  13. Kaim U., Moritz A., Failing K., Baumgärtner W. The regression of a canine Langerhans cell tumour is associated with increased expression of IL-2, TNF-alpha, IFN-gamma and iNOS mRNA. Immunology. 2006; 118(4): 472–482. 
  14. Puff C., Risha E., Baumgärtner W. Regression of canine cutaneous histiocytoma is associated with an orchestrated expression of matrix metalloproteinases. J Comp Pathol. 2013; 149(2-3): 208–215. doi: 10.1016/j.jcpa.2013.01.014. 
  15. Pires I., Queiroga F.L., Alves A., Silva F., Lopes C. Decrease of E-cadherin expression in canine cutaneous histiocytoma appears to be related to its spontaneous regression. Anticancer Res. 2009; 29(7): 2713–2717.
  16. Faller M., Lamm C., Affolter V.K., Valerius K., Schwartz S., Moore P.F. Retrospective characterisation of solitary cutaneous histiocytoma with lymph node metastasis in eight dogs. J Small Anim Pract. 2016; 57(10): 548–552. doi: 10.1111/jsap.12531. 
  17. Frye F.L., Carney J., Cucuel J.P. Generalized eruptive histiocytoma in a dog. J Am Vet Med Assoc. 1969;155(9):1465–1466. Garma-Avina A., Fromer E.. Generalized cutaneous histiocytoma in a dog (a case report). Vet Med Small Anim Clin. 1979; 74(9): 1269–1270.
  18. Bender W.M., Muller G.H. Multiple, resolving, cutaneous histiocytoma in a dog. J Am Vet Med Assoc. 1989; 194(4): 535–537.
  19. Nagata M., Hirata M., Ishida T. Progressive Langerhans’ cell histiocytosis in a puppy. Vet Dermatol. 2000;11(4): 241–246. 
  20. Maina E., Colombo S., Stefanello D. Multiple cutaneous histiocytomas treated with lomustine in a dog. Vet Dermatol. 2014; 25(6): 559–562, e98-99. doi: 10.1111/vde.12147.  
  21. Busch M.D., Reilly C.M., Luff J.A., Moore P.F. Feline pulmonary Langerhans cell histiocytosis with multiorgan involvement. Vet Pathol. 2008; 45(6): 816–824. doi: 10.1354/vp.45-6-816.
  22. Vassalo R., Ryu J.H. Pulmonary Langerhans’ cell histiocytosis.  Clin Chest Med. 2004; 25(3): 561 – 571.
  23. Affolter V.K., Moore P.F. Localized and disseminated histiocytic sarcoma of dendritic cell origin in dogs. Veterinary Pathology. 2002; 39: 74–83.
  24. Craig L.E., Julian M.E., Ferracone J.D. The diagnosis and prognosis of synovial tumors in dogs: 35 cases. Veterinary Pathology. 2002; 39: 66–73.
  25. Fidel J., Schiller I., Hauser B.,  Jausi Y., Rohrer-Bley C., Roos M., Kaser-Hotz B. Histiocytic sarcomas in flat-coated retrievers: a summary of 37 cases (November 1998 – March 2005). Vet Comp Oncol. 2006; 4(2): 63–74. doi: 10.1111/j.1476-5810.2006.00090.x.
  26. Skorupski K.A., Clifford C.A., Paoloni M.C., Lara-Garcia A., Barber L., Kent M.S., LeBlanc A.K., Sabhlok A., Mauldin E.A., Shofer F.S., Couto C.G., Sørenmo K.U. CCNU for the treatment of dogs with histiocytic sarcoma. J Vet Intern Med. 2007; 21(1):121–126.
  27. Constantino-Casas F., Mayhew D., Hoather T.M., Dobson J.M. The clinical presentation and histopathologic-immunohistochemical classification of histiocytic sarcomas in the flat-coated retriever. Vet Pathology. 2011; 48(3): 764–771. doi: 10.1177/0300985810385153. 
  28. Clifford C.A., Skorupski K.A., Moore P.F. Histiocytic diseases. In: Withrow S.J., Vail D.M., Page R., eds. Withrow & MacEwen's Small Animal Clinical Oncology. 5th. W.B. Saunders; Philadelphia, PA, USA: 2012. pp. 706–714.
  29. Erich S.A., Rutteman G.R., Teske E. Causes of death and the impact of histiocytic sarcoma on the life expectancy of the Dutch population of Bernese mountain dogs and flat-coated retrievers. Vet J. 2013;198(3): 678–683. doi: 10.1016/j.tvjl.2013.09.062.  
  30. Dervisis N.G., Kiupel M., Qin Q., Cesario L. Clinical prognostic factors in canine histiocytic sarcoma. Vet Comp Oncol. 2017; 15(4): 1171–1180. doi: 10.1111/vco.12252.
  31. Takahashi M., Tomiyasu H., Hotta E., Asada H., Fukushima K., Kanemoto H., Fujino Y., Ohno K., Uchida K., Nakayama H., Tsujimoto H. Clinical characteristics and prognostic factors in dogs with histiocytic sarcomas in Japan. J Vet Med Sci. 2014; 76(5): 661–666.
  32. Kagawa Y., Nakano Y., Kobayashi T., Asano K., Takagi S. Localized pulmonary histiocytic sarcomas in Pembroke Welsh Corgi. J Vet Med Sci. 2015; 77(12): 1659–1661. doi: 10.1292/jvms.15-0284.
  33. Mariani C.L., Jennings M.K., Olby N.J., Borst L.B., Brown J.C. Jr., Robertson I.D., Seiler G.S., MacKillop E. Histiocytic sarcoma with central nervous system involvement in dogs: 19 cases (2006-2012). J Vet Int Medicine. 2015; 29(2): 607–613. doi: 10.1111/jvim.12554.
  34. Lenz J.A., Furrow E., Craig L.E., Cannon C.M. Histiocytic sarcoma in 14 miniature schnauzers - a new breed predisposition? J Small Anim Pract. 2017; 58(8): 461–467. doi: 10.1111/jsap.12688. 
  35. Schultz R.M., Puchalski S.M., Kent M., Moore P.F. Skeletal lesions of histiocytic sarcoma in nineteen dogs. Vet Radiol Ultrasound. 2007; 48(6): 539–543.  
  36. Ide T., Uchida K., Kagawa Y., Suzuki K., Nakayama H. Pathological and immunohistochemical features of subdural histiocytic sarcomas in 15 dogs. J Vet Diagn Invest. 2011; 23(1): 127–132.
  37. Erich S.A., Constantino-Casas F., Dobson J.M., Teske E. Morphological distinction of histiocytic sarcoma from other tumor types in Bernese Mountain Dogs and Flatcoated Retrievers. In Vivo. 2018; 32(1): 7–17.
  38. Hostettler F.C., Wiener D.J., Welle M.M., Posthaus H., Geissbuhler U. Post mortem computed tomography and core needle biopsy in comparison to autopsy in eleven Bernese mountain dogs with histiocytic sarcoma. BMC Vet Res. 2015; 11: 229. doi 10.1186/s12917-015-0544 
  39. Asada H., Tsuboi M., Chambers J.K., Uchida K., Tomiyasu H., Goto-Koshino Y., Ohno K., Tsujimoto H. A 2-base insertion in exon 5 is a common mutation of the TP53 gene in dogs with histiocytic sarcoma. J Vet Med Sci. 2017; 79(10): 1721–1726. doi: 10.1292/jvms.17-0197.  
  40. Marlowe K.W., Robat C.S., Clarke D.M., Taylor A., Touret M., Husbands B.D., Vail D.M. Primary pulmonary histiocytic sarcoma in dogs: A retrospective analysis of 37 cases (2000-2015). Vet Comp Oncol. 2018; 16(4): 658–663. doi: 10.1111/vco.12437.  
  41. Cannon C., Borgatti A., Henson M., Husbands B. Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma. J Small Anim Pract. 2015; 56(7): 425–429.
  42. Mason S.L., Finotello R., Blackwood L. Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy. Vet Comp Oncol. 2018; 16(1): E30–E37. doi: 10.1111/vco.12329.
  43. Kezer K.A., Barber L.G., Jennings S.H. Efficacy of dacarbazine as a rescue agent for histiocytic sarcoma in dogs. Vet Comp Oncol. 2018; 16(1): 77–80. doi: 10.1111/vco.12314.
  44. Hafeman S.D., Varland D., Dow S.W. Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells. Vet Comp Oncol. 2012; 10(1): 44–56. doi: 10.1111/j.1476-5829.2011.00274.x.   
  45. Hedan B., Thomas R., Motsinger-Reif A., Abadie J., Andre C., Cullen J., Breen M. Molecular cytogenetic characterization of canine histiocytic sarcoma: A spontaneous model for human histiocytic cancer identifies deletion of tumor suppressor genes and highlights influence of genetic background on tumor behavior. BMC Cancer. 2011; 11: 201. doi: 10.1186/1471-2407-11-201.
  46. Thaiwong T., Sirivisoot S., Takada M., Yuzbasiyan-Gurkan V., Kiupel M. Gain-of-function mutation in PTPN11 in histiocytic sarcomas of Bernese Mountain Dogs. Vet Comp Oncol. 2018; 16(2): 220–228. doi: 10.1111/vco.12357. Wu X., Xu G., Li X., Xu W., Li Q., Liu W., Kirby K.A., Loh M.L., Li J., Sarafianos S.G., Qu C.K. A small molecule inhibitor that stabilizes the autoinhibited conformation of the oncogenic tyrosine phosphatase SHP2. J Med Chem. 2018. In press. doi: 10.1021/acs.jmedchem.8b00513.
  47. Ito K., Kuroki S., Kobayashi M., Ono K., Washizu T., Bonkobara M. Identification of dasatinib as an in vitro potent growth inhibitor of canine histiocytic sarcoma cells. Vet. J. 2013; 196 (3): 536–540. doi: 10.1016/j.tvjl.2012.12.016.
  48. Ito K., Miyamoto R., Tani H., Kurita S., Kobayashi M., Tamura K., Bonkobara M. Effect of dasatinib in a xenograft mouse model of canine histiocytic sarcoma and in vitro expression status of its potential target EPHA2. Vet Pharmacol Ther. 2018; 41(1): e45–e48. doi: 10.1111/jvp.12449. 
  49. Ruple A., Morley P.S. Risk factors associated with development of histiocytic sarcoma in Bernese Mountain Dogs. J Vet Intern Med 2016; 30: 1197–1203. doi: 10.1111/jvim.13964.
  50. Klahn S.L., Kitchell B.E., Dervisis N.G. Evaluation and comparison of outcomes in dogs with periarticular and nonperiarticular histiocytic sarcoma. J Am Vet Med Assoc. 2011; 239(1): 90–96. doi: 10.2460/javma.239.1.90.
  51. Moore A.S., Taylor D.P., Reppas G., Frimberger A.E. Chemotherapy for dogs with lymph node metastasis from histiocytic sarcomas. Aust Vet J. 2017; 95(1-2): 37–40. doi: 10.1111/avj.12522.
  52. Treggiari E., Ressel L., Polton G.A., Benoit J., Desmas I., Blackwood L. Clinical outcome, PDGFRβ and KIT expression in feline histiocytic disorders: a multicentre study. Vet Comp Oncol. 2017;15(1): 65–77. doi: 10.1111/vco.12142.  
  53. Affolter V.K., Moore P.F. Feline progressive histiocytosis. Vet Pathol . 2006; 43(5): 646–655.
  54. Pinto da Cunha N., Ghisleni G., Scarampella F., Fabbrini F., Sforna M., Cornegliani L., Caniatti M., Avallone G., Moore P., Roccabianca P. Cytologic and immunocytochemical characterization of feline progressive histiocytosis. Vet Clin Pathol. 2014; 43(3): 428–436. doi: 10.1111/vcp.12152.  
  55. Palmeiro B.S., Morris D.O., Goldschmidt M.H., Mauldin E.A. Cutaneous reactive histiocytosis in dogs: a retrospective evaluation of 32 cases. Vet Dermatol. 2007; 18(5): 332–340.
  56. Affolter V.K., Moore P.F. Canine cutaneous and systemic histiocytosis: reactive histiocytosis of dermal dendritic cells. Am J Dermatopathol. 2000; 22(1): 40–48.
  57. Allison R.W., Brunker J.D., Breshears M.A., Avery A.C., Moore P.F., Affolter V.K., Vernau W. Dendritic cell leukemia in a Golden Retriever. Vet Clin Pathol. 2008; 37(2): 190–197. doi: 10.1111/j.1939-165X.2008.00042.x.
  58. Rossi S., Gelain M.E., Comazzi S. Disseminated histiocytic sarcoma with peripheral blood involvement in a Bernese Mountain Dog. Vet Clin Pathol. 2009; 38(1): 126–130. 
  59. Moore P.F., Affolter V.K., Vernau W. Canine hemophagocytic histiocytic sarcoma: a proliferative disorder of CD11d+ macrophages. Vet Pathol. 2006; 43(5): 632–645.
  60. Friedrichs K.R., Young K.M. Histiocytic sarcoma of macrophage origin in a cat: case report with a literature review of feline histiocytic malignancies and comparison with canine hemophagocytic histiocytic sarcoma. Vet Clin Pathol. 2008; 37(1): 121–128. doi: 10.1111/j.1939-165X.2008.00005.x.